HCW Biologics Restates Q1 EPS Down 37% to $1.39, Cites Unremediated Material Weakness
HCWB sits 80% above its 52-week low of $1.5 on light trading volume (0.1× avg).
Summary
HCW Biologics filed its 10-Q/A restating Q1 2026 EPS from $2.19 to $1.39 due to a warrant accounting error, and disclosed that material weaknesses in internal controls remain unremediated.
Key Events · Earnings and Guidance · HCWB
-
EPS Restated Down 37%
Q1 2026 basic and diluted EPS restated from $2.19 to $1.39 after applying the two-class method to participating warrants, reducing net income attributable to common stockholders by $728,299.
-
Material Weakness Unremediated
Management confirms the material weakness in technical accounting review control over complex warrant instruments has not been remediated, and a separate material weakness related to long-lived asset impairment also remains.
-
Going Concern Doubt Persists
The filing reiterates substantial doubt about the company's ability to continue as a going concern, with cumulative net losses of $102.3 million and negative working capital as of March 31, 2026.
-
Nasdaq Compliance Risk
The company is awaiting a Nasdaq Hearings Panel determination on its bid price compliance plan, with the stock trading at $2.70 after a 1-for-6 reverse split.
Analysis · HCWB · Life Sciences
The restated Q1 2026 EPS of $1.39 is 37% lower than the previously reported $2.19, driven by the misapplication of the two-class method for participating warrants. The company also confirms that the material weakness in technical accounting review remains unremediated, and a second material weakness related to long-lived asset impairment persists. This raises serious concerns about the reliability of financial reporting for a company already facing going concern doubts and Nasdaq compliance issues.
At the time of this filing, HCWB was trading at $2.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3M. The 52-week trading range was $1.50 to $44.10. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.